Results 151 to 160 of about 36,003 (284)

Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study

Developmental Medicine &Child Neurology, EarlyView.
This multicenter retrospective study evaluated the use of intravenous immunoglobulin (IVIG) in 14 children with Dravet syndrome as a preventive strategy against febrile status epilepticus. Over a 6‐month period, IVIG was associated with a significant reduction in hospitalizations for febrile status epilepticus.
Romane Marc, Nicole Chemaly, Mathieu Kuchenbuch, Caroline Espil‐Taris, Elodie Lametery, Hélène Maurey, Sylviane Peudenier, Sylvie Nguyen The Tich, Rima Nabbout, Claire Bar   +9 more
wiley   +1 more source

Evaluating cognitive effects of topiramate in trauma-focused treatment: Findings from a randomized double-blind clinical trial of veterans with PTSD and alcohol use disorder. [PDF]

Psychol Trauma
Hicks TA, Dell KC, Klein AB, Oca ZM, McCue ML, Jak AJ, Martis B, Norman SB.   +7 more
europepmc   +1 more source

Seizures in children with Dravet syndrome in extreme heat: A qualitative study of parental perspectives

Developmental Medicine &Child Neurology, EarlyView.
Perspectives of parents of children with Dravet syndrome indicate that extreme heat and high temperatures exacerbate epileptic seizures, introduce new seizure triggers, and require the adoption of specific seizure‑management strategies. Abstract Aim To describe parental perspectives on how heatwaves and high ambient temperatures influence seizure ...
Angel Aledo‐Serrano, José Ángel Aibar, Domingo Palacios‐Ceña, Maria Salcedo‐Perez‐Juana, Maria Palacios‐Ceña, Simona Giorgi, Manuel Lorenzo‐Dieguez, Sanjay M Sisodiya, Cristina García‐Bravo   +8 more
wiley   +1 more source

Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To describe obesity treatments in real‐world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post‐discontinuation. Materials and Methods This retrospective cohort study used electronic health records from 1 January 2021, to 30 June 2025, in a large health system in Ohio and Florida.
Hamlet Gasoyan, Rebecca Schulte, Christopher B. Boyer, Nicholas J. Casacchia, W. Scott Butsch, Phuc Le, Ali Aminian, Marcio L. Griebeler, Bartolome Burguera, Michael B. Rothberg   +9 more
wiley   +1 more source

Ocular changes in patients on Topiramate therapy: a hospital-based comparative study. [PDF]

BMC Ophthalmol
Patro M, Mishra S, Pattnaik S, Panigrahi PK.   +3 more
europepmc   +1 more source

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna, Carlos Mena‐Hurtado, Victoria Divino, Zhenxiang Zhao, Yan Chen, Joanna Boland, Jinlin Song, Andrea Traina, Kerem Ozer, Filip K. Knop, Kim G. Smolderen   +10 more
wiley   +1 more source

Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study. [PDF]

PLoS One
Choi SY, Oh SY, Kim HA, Park JY, Choi JH, Oh EH, Choi JY, Jeong SH, Lee SH, Kim JM, Kim SH, Kim HJ, Choi KD, Kim JS.   +13 more
europepmc   +1 more source

Semaglutide 2.4 mg Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States (SMILE)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the real‐world associations between semaglutide 2.4 mg and cardiometabolic comorbidities, biomarkers and cardiovascular risk among adults with overweight or obesity. Methods This retrospective cohort study used US claims data and laboratory measurements from the Komodo Research Database (2016–2024). Adults with obesity or with
Aleksandrina Ruseva, Wojciech Michalak, Matthew Bassan, Ella Xiaoyan Du, Anthony Fabricatore, Bríain Ó Hartaigh, Theo Man, Ramya Ramasubramanian, Pangsibo Shen, Jinlin Song, Zhenxiang Zhao, Francisco Lopez‐Jimenez   +11 more
wiley   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Effectiveness and acceptability of oral migraine preventives: A prospective, observational study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To explore the adherence, effectiveness, safety, tolerability, and acceptability of frequently used oral migraine preventive drugs in a real‐world setting. Background Oral migraine preventives are previously mainly explored in randomized controlled trials, whereas real‐world data on treatment outcomes remain limited. Methods MigriNor
Hedda S. Riise, Melanie R. Simpson, Ketil A. Espnes, Erling A. Tronvik, Andreas K. Husøy, Lise R. Øie, Anker Stubberud, Emil Kofoed, Aurora H. Alstad, Hedda H. Hagen, Maren G. Lien, Marie L. Stavseng, Ella R. Sæther, Tore Wergeland   +13 more
wiley   +1 more source